Mechanism of MALT1 Regulation by a Novel Ubiquitin Ligase
新型泛素连接酶调节 MALT1 的机制
基本信息
- 批准号:8821943
- 负责人:
- 金额:$ 22.74万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2015
- 资助国家:美国
- 起止时间:2015-04-13 至 2017-03-31
- 项目状态:已结题
- 来源:
- 关键词:ApoptosisAutoimmune DiseasesAutoimmune ResponsesBindingBiologicalBiological AssayCell SurvivalCellsChronicCisplatinClinicComplexDataDemyelinationsDevelopmentDiseaseDrug DesignDrug TargetingEnsureExperimental Autoimmune EncephalomyelitisGoalsHumanImmuneImmune responseImmune systemImmunotherapyIn VitroInfiltrationInflammatoryInterleukin-17InvestigationKnockout MiceLaboratoriesLengthLymphomaLysineMalignant NeoplasmsMass Spectrum AnalysisMediatingModificationMolecularMultiple SclerosisMutagenesisNF-kappa BNeuraxisPathway interactionsPlayPost-Translational Protein ProcessingProductionProteinsProtocols documentationRegulationResearchRoleSeveritiesSignal TransductionSiteSpecificityStructureT-LymphocyteTertiary Protein StructureTherapeuticUbiquitinUbiquitinationWorkX-Ray Crystallographybasecancer cellcancer therapyclinically relevantcytokinehigh rewardhuman diseasein vivoinfancyinnovationinsightknock-downmalignant breast neoplasmmouse modelmutantneoplastic cellnovelpublic health relevanceresearch studyresponsetherapeutic targettherapy developmentubiquitin ligaseubiquitin-protein ligase
项目摘要
DESCRIPTION (provided by applicant): E3 Ubiquitin ligases have been attractive therapeutic targets in cancer, due to their major biological roles, and target specificity, however their use i development of therapies for autoimmune disorders remains in infancy. Recently, we found that a novel ubiquitin E3 ligase HECTD3 interacts and ubiquitinates MALT1, which is a critical positive regulator of the transcription factor NF-kB in immune cells and strongly contributes to cell survival in lymphomas and plays an essential role in multiple sclerosis, a chronic inflammatory disease associated with demyelination of central nervous system. The MALT1 ubiquitination mediated by HECTD3 leads to MALT1 stabilization, and promotes cancer cell survival of cisplatin-induced apoptosis, and plays a critical role in Experimental Autoimmune Encephalomyelitis (EAE), a mouse model for multiple sclerosis in humans. We also found that HECTD3 knock-out mice have reduced EAE severity, diminished Th17 cytokine production, lower levels of MALT1 and its ubiquitination, and reduced infiltration of Th17 cells into the central nervous system, suggesting that HECTD3 controls the Th17 response in EAE through MALT1 regulation. Despite the importance of HECTD3 in these diseases, very little is known about the structure of HECTD3 and its mechanism of action on MALT1. Thus, the major goal of this proposal is to decipher the mechanisms of HECTD3 in MALT1 regulation. Specifically, we propose to investigate the molecular mechanisms by which HECTD3 contributes to MALT1 modifications using in vitro, in vivo, and structural approaches. The proposed studies will result in detailed molecular insights into MALT1 ubiquitination and regulation by HECTD3, as well as details on the HECTD3-MALT1 interactions. Ultimately, data generated by this study will serve as a starting point for development of more specific and more effective immune therapies against lymphomas, multiple sclerosis, and breast cancer, which is of major importance, given the current treatment challenges and the reduced therapeutic options.
描述(由申请人提供):E3泛素连接酶由于其主要的生物学作用和靶特异性而成为癌症中有吸引力的治疗靶标,然而其在开发自身免疫性疾病的疗法中的用途仍处于婴儿期。最近,我们发现一种新的泛素E3连接酶HECTD 3相互作用并泛素化MALT 1,MALT 1是免疫细胞中转录因子NF-kB的关键正调节因子,对淋巴瘤中的细胞存活有很大贡献,并在多发性硬化症(一种与中枢神经系统脱髓鞘相关的慢性炎症性疾病)中起重要作用。由HECTD 3介导的MALT 1泛素化导致MALT 1稳定,并促进顺铂诱导的细胞凋亡的癌细胞存活,并且在实验性自身免疫性脑脊髓炎(EAE)(人类多发性硬化症的小鼠模型)中起关键作用。我们还发现,HECTD 3基因敲除小鼠EAE严重程度降低,Th 17细胞因子产生减少,MALT 1及其泛素化水平降低,Th 17细胞向中枢神经系统的浸润减少,表明HECTD 3通过MALT 1调节控制EAE中的Th 17反应。尽管HECTD 3在这些疾病中的重要性,但对HECTD 3的结构及其对MALT 1的作用机制知之甚少。因此,该提案的主要目标是破译HECTD 3在MALT 1调节中的机制。具体来说,我们建议调查的分子机制,HECTD 3有助于MALT 1修改使用在体外,体内和结构的方法。拟议的研究将导致对MALT 1泛素化和HECTD 3调控的详细分子见解,以及HECTD 3-MALT 1相互作用的细节。最终,本研究生成的数据将作为开发针对淋巴瘤、多发性硬化症和乳腺癌的更特异、更有效的免疫疗法的起点,考虑到当前的治疗挑战和减少的治疗选择,这一点至关重要。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
HONGMIN LI其他文献
HONGMIN LI的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('HONGMIN LI', 18)}}的其他基金
Development of Inhibitors Targeting Flavivirus Methyltransferase
黄病毒甲基转移酶抑制剂的开发
- 批准号:
10636605 - 财政年份:2023
- 资助金额:
$ 22.74万 - 项目类别:
Discovery of therapeutics against Cryptococcosis by Repurposing Pharmaceutical Libraries
通过重新利用药物库发现隐球菌病的治疗方法
- 批准号:
10308245 - 财政年份:2019
- 资助金额:
$ 22.74万 - 项目类别:
High throughput screening of the Prp8 intein splicing inhibitors for pathogenic fungi
病原真菌 Prp8 内含肽剪接抑制剂的高通量筛选
- 批准号:
10319642 - 财政年份:2018
- 资助金额:
$ 22.74万 - 项目类别:
High throughput screening of orthosteric inhibitors of flavivirus protease
黄病毒蛋白酶正构抑制剂的高通量筛选
- 批准号:
10376239 - 财政年份:2018
- 资助金额:
$ 22.74万 - 项目类别:
High throughput screening of orthosteric inhibitors of flavivirus protease
黄病毒蛋白酶正构抑制剂的高通量筛选
- 批准号:
10318299 - 财政年份:2018
- 资助金额:
$ 22.74万 - 项目类别:
High throughput screening of the Prp8 intein splicing inhibitors for pathogenic fungi
病原真菌 Prp8 内含肽剪接抑制剂的高通量筛选
- 批准号:
10382470 - 财政年份:2018
- 资助金额:
$ 22.74万 - 项目类别:
High throughput screening of orthosteric inhibitors of flavivirus protease
黄病毒蛋白酶正构抑制剂的高通量筛选
- 批准号:
9538444 - 财政年份:2017
- 资助金额:
$ 22.74万 - 项目类别:
Mechanism of MALT1 Regulation by a Novel Ubiquitin Ligase
新型泛素连接酶调节 MALT1 的机制
- 批准号:
9053450 - 财政年份:2015
- 资助金额:
$ 22.74万 - 项目类别:
相似国自然基金
Autoimmune diseases therapies: variations on the microbiome in rheumatoid arthritis
- 批准号:31171277
- 批准年份:2011
- 资助金额:60.0 万元
- 项目类别:面上项目
相似海外基金
Effects of maternal immune activation on autoimmune diseases in offsprings
母体免疫激活对后代自身免疫性疾病的影响
- 批准号:
23H02155 - 财政年份:2023
- 资助金额:
$ 22.74万 - 项目类别:
Grant-in-Aid for Scientific Research (B)
Autoantibodies and antibody-secreting cells in neurological autoimmune diseases: from biology to therapy
神经性自身免疫性疾病中的自身抗体和抗体分泌细胞:从生物学到治疗
- 批准号:
479128 - 财政年份:2023
- 资助金额:
$ 22.74万 - 项目类别:
Operating Grants
IPP: AUTOIMMUNE DISEASES STATISTICAL AND CLINICAL COORDINATING CENTER (ADSCCC)
IPP:自身免疫性疾病统计和临床协调中心 (ADSCCC)
- 批准号:
10788032 - 财政年份:2023
- 资助金额:
$ 22.74万 - 项目类别:
Biomarkers of vascular endothelial dysfunction in systemic autoimmune diseases: analysis of circulating microRNAs
系统性自身免疫性疾病中血管内皮功能障碍的生物标志物:循环 microRNA 分析
- 批准号:
23K14742 - 财政年份:2023
- 资助金额:
$ 22.74万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
NOVEL HUMORAL AND CELLULAR BIOMARKERS OF AUTOIMMUNE DISEASES CAUSED BY IMMUNOTHERAPY
免疫治疗引起的自身免疫性疾病的新型体液和细胞生物标志物
- 批准号:
10593224 - 财政年份:2023
- 资助金额:
$ 22.74万 - 项目类别:
Structural mechanisms of autoimmune diseases targeting cys-loop receptors
针对半胱氨酸环受体的自身免疫性疾病的结构机制
- 批准号:
10864719 - 财政年份:2023
- 资助金额:
$ 22.74万 - 项目类别:
Developing non-immunosuppressive immune-based therapeutics for targeted treatment of autoimmune diseases
开发非免疫抑制性免疫疗法来靶向治疗自身免疫性疾病
- 批准号:
10586562 - 财政年份:2023
- 资助金额:
$ 22.74万 - 项目类别:
Regulation of autoimmune diseases by PTPN22 phosphatase
PTPN22磷酸酶对自身免疫性疾病的调节
- 批准号:
23K06589 - 财政年份:2023
- 资助金额:
$ 22.74万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Decipher and target GABA metabolism and GABA receptor-mediated signaling in autoimmune diseases
破译并靶向自身免疫性疾病中的 GABA 代谢和 GABA 受体介导的信号传导
- 批准号:
10623380 - 财政年份:2023
- 资助金额:
$ 22.74万 - 项目类别:
Targeting the long isoform of the prolactin receptor to treat autoimmune diseases and B-cell malignancies
靶向催乳素受体的长亚型来治疗自身免疫性疾病和 B 细胞恶性肿瘤
- 批准号:
10735148 - 财政年份:2023
- 资助金额:
$ 22.74万 - 项目类别:














{{item.name}}会员




